Company intelligence / Profile preview

Cosmo Bioscience

Ownership: Private
Development stage: Commercial

Overview

Cosmo Bio is a leading Japanese life science trading company specializing in the distribution of advanced reagents, antibodies, proteins, kits, and laboratory equipment to support global biomedical and life science research. The US subsidiary has also participated as sponsor/collaborator in at least one discontinued Phase 2 clinical trial of an investigational cancer vaccine targeting telomerase in melanoma.

Modalities: AntibodySmall moleculeRecombinant proteinPeptidesVaccine
Industry: Chemicals & Materials

Partnerships

MBL Life Sciences (exclusive US distribution partnership)Over 600 global suppliers/manufacturers for reagent distribution

Beyond the preview

Go deeper on Cosmo Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cosmo Bioscience.

Explore the full profile